Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prophylactic vs preemptive oral valganciclovir for management of cytomegalovirus infection in adult renal transplant recipients: a clinical and pharmacoeconomic study

Trial Profile

Prophylactic vs preemptive oral valganciclovir for management of cytomegalovirus infection in adult renal transplant recipients: a clinical and pharmacoeconomic study

Completed
Phase of Trial: Phase III

Latest Information Update: 22 Oct 2006

At a glance

  • Drugs Valganciclovir (Primary)
  • Indications Cytomegalovirus infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top